Akt inhibitors: mechanism of action and implications for anticancer therapeutics

Akt, better known as protein kinase B (PKB), is a serine/threonine-specific protein kinase which acts as mediator via PI3K/Akt pathway in many biological processes like glucose metabolism, apoptosis, cell differentiation and transcription. Akt1 gene amplification has been implicated in gastric carci...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhutani, Jaikrit, Sheikh, Asfandyar, Niazi, Asfandyar Khan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028840/
https://www.ncbi.nlm.nih.gov/pubmed/24330834
http://dx.doi.org/10.1186/1750-9378-8-49
_version_ 1782317113533267968
author Bhutani, Jaikrit
Sheikh, Asfandyar
Niazi, Asfandyar Khan
author_facet Bhutani, Jaikrit
Sheikh, Asfandyar
Niazi, Asfandyar Khan
author_sort Bhutani, Jaikrit
collection PubMed
description Akt, better known as protein kinase B (PKB), is a serine/threonine-specific protein kinase which acts as mediator via PI3K/Akt pathway in many biological processes like glucose metabolism, apoptosis, cell differentiation and transcription. Akt1 gene amplification has been implicated in gastric carcinoma while Akt2 amplification has been linked with ovarian, pancreas, breast and stomach tumors. The use of Akt inhibitors as monotherapy or in combination with other anticancer drugs could be useful for combating drug resistance and improving response. Thus, comprehensive understanding of Akt and its linked signaling pathways (PI3K, PKB, mTOR etc.) is necessary to lead to newer drug development and use.
format Online
Article
Text
id pubmed-4028840
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40288402014-05-22 Akt inhibitors: mechanism of action and implications for anticancer therapeutics Bhutani, Jaikrit Sheikh, Asfandyar Niazi, Asfandyar Khan Infect Agent Cancer Letter to the Editor Akt, better known as protein kinase B (PKB), is a serine/threonine-specific protein kinase which acts as mediator via PI3K/Akt pathway in many biological processes like glucose metabolism, apoptosis, cell differentiation and transcription. Akt1 gene amplification has been implicated in gastric carcinoma while Akt2 amplification has been linked with ovarian, pancreas, breast and stomach tumors. The use of Akt inhibitors as monotherapy or in combination with other anticancer drugs could be useful for combating drug resistance and improving response. Thus, comprehensive understanding of Akt and its linked signaling pathways (PI3K, PKB, mTOR etc.) is necessary to lead to newer drug development and use. BioMed Central 2013-12-13 /pmc/articles/PMC4028840/ /pubmed/24330834 http://dx.doi.org/10.1186/1750-9378-8-49 Text en Copyright © 2013 Bhutani et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to the Editor
Bhutani, Jaikrit
Sheikh, Asfandyar
Niazi, Asfandyar Khan
Akt inhibitors: mechanism of action and implications for anticancer therapeutics
title Akt inhibitors: mechanism of action and implications for anticancer therapeutics
title_full Akt inhibitors: mechanism of action and implications for anticancer therapeutics
title_fullStr Akt inhibitors: mechanism of action and implications for anticancer therapeutics
title_full_unstemmed Akt inhibitors: mechanism of action and implications for anticancer therapeutics
title_short Akt inhibitors: mechanism of action and implications for anticancer therapeutics
title_sort akt inhibitors: mechanism of action and implications for anticancer therapeutics
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028840/
https://www.ncbi.nlm.nih.gov/pubmed/24330834
http://dx.doi.org/10.1186/1750-9378-8-49
work_keys_str_mv AT bhutanijaikrit aktinhibitorsmechanismofactionandimplicationsforanticancertherapeutics
AT sheikhasfandyar aktinhibitorsmechanismofactionandimplicationsforanticancertherapeutics
AT niaziasfandyarkhan aktinhibitorsmechanismofactionandimplicationsforanticancertherapeutics

Ejemplares similares